期刊文献+

姜黄素可缓解多囊卵巢综合征大鼠卵巢炎症状态并改善其功能 被引量:6

Curcumin can alleviate ovarian inflammation and improve its function in rats with polycystic ovarian syndrome
原文传递
导出
摘要 为探讨姜黄素对多囊卵巢综合征(polycystic ovarian syndrome, PCOS)大鼠模型血清性激素水平及组织中免疫因子IL-6、CRP、TNF-α表达的影响,将70只雌性SD大鼠随机分为正常组(10只)和造模组(60只)。造模成功后将其分为PCOS模型组、高、中、低药物治疗组,给予各组大鼠腹腔注射姜黄素,治疗结束后收集大鼠血清并分离卵巢进行检测,计算卵巢指数、大鼠体质量;采用血糖检测仪检测各组大鼠空腹血糖(fasting blood glucose, FBG)、空腹血清胰岛素(fasting serum insulin, FINS)和稳态模型胰岛素抵抗指数(homeostasis model assessment-insulin resistance index, HOMA-IR)水平;采用ELISA检测试剂盒检测血清性激素[卵泡刺激素(follicle-stimulating hormone, FSH)、雌二醇(estradiol, E_(2))、黄体生成素(luteinizing hormone, LH)、孕酮(progesterone, P)、睾酮(testosterone, T)]水平及TNF-α、IL-6、CRP水平;采用免疫组织化学法检测卵巢组织中TNF-α和IL-6的表达。血清及组织学检测结果显示,药物治疗组与PCOS组相比血清中性激素及FBG、FINS、HOMA-IR水平得到改善(P<0.05);TNF-α、IL-6、CRP等炎性因子水平显著减少(P<0.05);PCOS组卵泡和卵巢颗粒层中TNF-α及IL-6表达水平显著高于正常组(P<0.05),药物干预后表达量显著降低(P<0.05)。研究提示,姜黄素对PCOS的炎症改善作用与其抑制TNF-α、IL-6和CRP的表达有关,可能通过此途径改善性激素水平并调节血糖水平。 To investigate the effects of curcumin on serum sex hormone levels and the expression of IL-6, CRP, and TNF-α in ovarian tissues of polycystic ovarian syndrome(PCOS) rat models, 70 female SD rats were randomly divided into the normal group(n=10) and model group(n=60). After successful modeling, the rats were divided into PCOS model group, high, medium, and low curcumin treatment groups. Curcumin was intraperitoneally injected into the rats in each group. At the end of the treatment, the serum was collected and ovaries were separated for detection, ovarian index and rat body weight were calculated. Fasting blood glucose(FBG), fasting serum insulin(FINS), homeostasis model assessment-insulin resistance index(HOMA-IR) were measured by blood glucose monitor. Follicle-stimulating hormone(FSH), estradiol(E_(2)), luteinizing hormone(LH), progesterone(P), testosterone(T), TNF-α, IL-6, and CRP levels in serum were measured by ELISA. Besides, TNF-α, IL-6, and CRP in the ovarian tissue were determined by immunohistochemistry. The results showed that, compared with PCOS group, the levels of serum sex hormone, FBG, FINS and HOMA-IR in drug treatment group were improved(all P<0.05);the levels of inflammatory factors such as TNF-α, IL-6, and CRP were significantly decreased(all P<0.05);the expression levels of TNF-α and IL-6 in follicle and ovarian granular layer in PCOS group were significantly higher than those in the normal group(all P<0.05), but significantly decreased after drug intervention(all P<0.05). Our results suggest that curcumin could improve PCOS inflammation by inhibiting the expression of TNF-α, IL-6, and CRP, which may improve the levels of sex hormone and blood glucose.
作者 张韵函 谢盛言 何珊珊 ZHANG Yun-han;XIE Sheng-yan;HE Shan-shan(Department of Obstetrics and Gynecology,the Third Affiliated Hospital of Zunyi Medical University,the First People's Hospital of Zunyi City,Zunyi 563000,China)
出处 《现代免疫学》 CAS 北大核心 2021年第6期481-486,共6页 Current Immunology
关键词 C反应蛋白 姜黄素 白细胞介素6 多囊卵巢综合征 肿瘤坏死因子Α C-reactive protein curcumin interleukin-6 polycystic ovarian syndrome tumor necrosis factor-α
  • 相关文献

参考文献10

二级参考文献63

  • 1麻海英,刘复权.二甲双胍对多囊卵巢综合征患者的治疗作用[J].国外医学(妇幼保健分册),2004,15(4):243-245. 被引量:3
  • 2张秋芳,刘平.女性生殖衰老及其对人工助孕结局的影响[J].生殖与避孕,2005,25(8):491-494. 被引量:6
  • 3陈文成,潘尚领.抑癌基因与细胞衰老研究进展[J].医学综述,2006,12(12):711-713. 被引量:4
  • 4BukuLmez O, Arici A. Leukocytes in ovarian function [ J ] . Hum Reprod Update, 2000, 6 (1): 1.
  • 5Carmina E. Diagnosis of polycystic ovary syndrome : from NIH criteria to ESHRE - ASRM guidelines ( J ] . Minerva Ginecol, 2004, 56 ( 1 ) : 1.
  • 6Escobar- Morreale HF, Calvo RM, Sancho Jet al. TNF - alpha and hyperandrogenism: a clinical, biochemical, and molecular genetic study [J] . J Clin Endocrinol Metab, 2001, 86 (8) : 3761.
  • 7Fernamdez- Real JM, Broch M, Vendrell J et al. Interleukin -6 gene polymorphism and lipid abnormalities in healthy subjects [ J] . J Clin Endocrinol Metab, 2000, 85 (3) : 1334.
  • 8Goyenechea E, Parra MD, Martinez Hernandez JA. Role of IL -6 and its - 174G > C polymorphism in weight management and in the metabolic comorbidities associated with obesity [ J ] . An Sist Sanit Navar, 2005, 28 (3): 357.
  • 9De Leo V A, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome [ J ]. Endocr Rev, 2003,24 (5) : 633 -667.
  • 10Ovalle F, Azziz R. Insulin resistance, polycystie ovary syndrome, and type 2 diabetes mellitus[ J]. Fertil Stefil, 2002,77(6) : 1095 - 1105.

共引文献62

同被引文献72

引证文献6

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部